Ex vivo treatment of primary AML blasts with CVA21 identified a number of patients (n = 8 of 16) whose blasts were susceptible to CVA21 killing (see Additional file 6: Figure S4A), whilst CD45+ hematopoietic non-malignant cells remained unharmed (Additional file 6: Figure S4B). This evidence concerns the gene PTPRC and acute myeloid leukemia.